-
Brodalumab, sold
under the
brand name
Siliq in the US and
Kyntheum in the EU, is a
human monoclonal antibody designed for the
treatment of inflammatory...
- psoriasis.
There is also some
evidence to
support use of secukinumab,
brodalumab, guselkumab, certolizumab, and ustekinumab. In general, anti-IL17, anti-IL12/23...
- This
mechanism is
similar to that of
another anti-psoriasis antibody,
brodalumab,
which binds to the interleukin-17 receptor. The
antibody has affinity...
-
Human papillomavirus types 16 and 18. In September,
Valeant licensed Brodalumab from the
company for up to US$445 million. On 6 November, it was reported...
-
libido drug Addyi. In
September 2015,
Valeant licensed psoriasis drug
Brodalumab from
AstraZeneca for up to $445 million. In
September 2015, the company...
-
company in
conjunction with
AstraZeneca reported positive results for
brodalumab in a
Phase III
trial comparing the
compound with
ustekinumab and a placebo...
- Agonists:
Interleukin 17 (A, B, C, D, E (interleukin 25), F) Antibodies:
Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists:...
- Agonists:
Interleukin 17 (A, B, C, D, E (interleukin 25), F) Antibodies:
Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists:...
- Agonists:
Interleukin 17 (A, B, C, D, E (interleukin 25), F) Antibodies:
Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists:...
-
rheumatoid arthritis,
inflammatory bowel diseases,
multiple sclerosis Brodalumab Siliq mab
human IL-17 Y
Plaque psoriasis Brolucizumab Beovu scFv humanized...
